Delcath Systems (NASDAQ:DCTH) Price Target Increased to $20.00 by Analysts at HC Wainwright

Delcath Systems (NASDAQ:DCTH) had its price objective upped by HC Wainwright from $18.00 to $20.00 in a report published on Wednesday, Benzinga reports. They currently have a buy rating on the stock.

Delcath Systems Stock Performance

DCTH opened at $5.09 on Wednesday. The business has a fifty day simple moving average of $4.34 and a 200 day simple moving average of $3.84. The company has a market capitalization of $112.21 million, a PE ratio of -1.52 and a beta of 0.51. Delcath Systems has a 1 year low of $2.25 and a 1 year high of $7.99. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.30 and a quick ratio of 3.11.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Tuesday, March 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.19. The business had revenue of $0.54 million during the quarter, compared to the consensus estimate of $0.48 million. Delcath Systems had a negative return on equity of 2,571.64% and a negative net margin of 2,079.17%. During the same period in the previous year, the company posted ($0.86) EPS. Research analysts expect that Delcath Systems will post -2.64 EPS for the current year.

Insider Buying and Selling at Delcath Systems

In related news, Director Gil Aharon acquired 26,882 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was purchased at an average cost of $3.72 per share, with a total value of $100,001.04. Following the acquisition, the director now directly owns 1,069,710 shares of the company’s stock, valued at $3,979,321.20. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 21.10% of the company’s stock.

Hedge Funds Weigh In On Delcath Systems

A number of institutional investors have recently modified their holdings of the business. Vivo Capital LLC increased its holdings in Delcath Systems by 57.4% in the 3rd quarter. Vivo Capital LLC now owns 1,855,191 shares of the company’s stock worth $7,514,000 after purchasing an additional 676,404 shares in the last quarter. AIGH Capital Management LLC bought a new stake in shares of Delcath Systems in the 4th quarter valued at about $4,918,000. BVF Inc. IL bought a new stake in shares of Delcath Systems in the 2nd quarter valued at about $6,872,000. Stonepine Capital Management LLC grew its position in shares of Delcath Systems by 81.2% in the 3rd quarter. Stonepine Capital Management LLC now owns 686,240 shares of the company’s stock valued at $2,779,000 after buying an additional 307,453 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Delcath Systems by 19.7% in the 4th quarter. Vanguard Group Inc. now owns 522,008 shares of the company’s stock valued at $2,172,000 after buying an additional 85,948 shares during the last quarter. Institutional investors and hedge funds own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.